{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:49:15Z","timestamp":1787870955853,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40256-019-00353-5","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T07:17:02Z","timestamp":1560928622000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-0867","authenticated-orcid":false,"given":"Jolien","family":"Neefs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoline W. E.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien P. J.","family":"Krul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Matthijs","family":"Boekholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"issue":"38","key":"353_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J."},{"issue":"27","key":"353_CR2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J."},{"key":"353_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ijcard.2015.10.220","volume":"203","author":"D Kotecha","year":"2016","unstructured":"Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660\u20136.","journal-title":"Int J Cardiol"},{"issue":"10","key":"353_CR4","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","volume":"289","author":"D Lavall","year":"2014","unstructured":"Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schafers HJ, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289(10):6656\u201368.","journal-title":"J Biol Chem."},{"issue":"4","key":"353_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.tem.2015.01.007","volume":"26","author":"Y Parviz","year":"2015","unstructured":"Parviz Y, Iqbal J, Pitt B, Adlam D, Al-Mohammad A, Zannad F. Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends Endocrinol Metab. 2015;26(4):201\u201311.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"353_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCEP.107.754564","volume":"1","author":"S Nattel","year":"2008","unstructured":"Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circul Arrhythm Electrophysiol. 2008;1(1):62\u201373.","journal-title":"Circul Arrhythm Electrophysiol"},{"key":"353_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2016.12.029","volume":"231","author":"J Neefs","year":"2017","unstructured":"Neefs J, van den Berg NW, Limpens J, Berger WR, Boekholdt SM, Sanders P, et al. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017;231:155\u201361.","journal-title":"Int J Cardiol"},{"issue":"1","key":"353_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"353_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598\u2013603.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"353_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jchf.2018.05.005","volume":"6","author":"M Cikes","year":"2018","unstructured":"Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail. 2018;6(8):689\u201397.","journal-title":"JACC Heart Fail"},{"issue":"15","key":"353_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"6","key":"353_CR12","doi-asserted-by":"publisher","first-page":"966\u201372.e10","DOI":"10.1016\/j.ahj.2011.09.007","volume":"162","author":"AS Desai","year":"2011","unstructured":"Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162(6):966\u201372.e10.","journal-title":"Am Heart J"},{"issue":"1","key":"353_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34\u201342.","journal-title":"Circulation"},{"issue":"17","key":"353_CR14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT\u2014new insights into regional variation. N Engl J Med. 2017;376(17):1690\u20132.","journal-title":"N Engl J Med"},{"issue":"1","key":"353_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","volume":"47","author":"CW Yancy","year":"2006","unstructured":"Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47(1):76\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"353_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","volume":"5","author":"U Sartipy","year":"2017","unstructured":"Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5(8):565\u201374.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"353_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"353_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/CIRCHEARTFAILURE.114.001667","volume":"8","author":"V Melenovsky","year":"2015","unstructured":"Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail. 2015;8(2):295\u2013303.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"353_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73\u201390.","journal-title":"Circulation"},{"issue":"11","key":"353_CR20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.amjcard.2010.07.037","volume":"106","author":"R Dabrowski","year":"2010","unstructured":"Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, et al. Effect of combined spironolactone-beta-blocker +\/\u2212 enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol. 2010;106(11):1609\u201314.","journal-title":"Am J Cardiol"},{"issue":"6","key":"353_CR21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/0735-1097(94)90385-9","volume":"23","author":"CR Benedict","year":"1994","unstructured":"Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994;23(6):1410\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"353_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.pcad.2005.02.001","volume":"47","author":"K Hogg","year":"2005","unstructured":"Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Progress Cardiovasc Dis. 2005;47(6):357\u201366.","journal-title":"Progress Cardiovasc Dis"},{"issue":"22","key":"353_CR23","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102(22):2700\u20136.","journal-title":"Circulation."},{"issue":"10","key":"353_CR24","doi-asserted-by":"publisher","first-page":"e002137","DOI":"10.1161\/JAHA.115.002137","volume":"4","author":"A Pandey","year":"2015","unstructured":"Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, et al. Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review. J Am Heart Assoc. 2015;4(10):e002137.","journal-title":"J Am Heart Assoc"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00353-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T19:17:30Z","timestamp":1592421450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00353-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["353"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00353-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"assertion":[{"value":"19 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. de Groot is a consultant for AtriCure and Daichii Sankyo; has received research grants from AtriCure, Medtronic, Boston Scientific and Abbott and a grant from ZonMW\/now (106.146.310) outside the submitted work. Jolien Neefs, Nicoline van den Berg, S\u00e9bastien Krul and S. Matthijs Boekholdt have no potential conflicts of interest that might be relevant to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}